New treatment approved for soft-tissue cancers

(HealthDay)—Lartruvo (olaratumab) has been approved by the U.S. Food and Drug Administration to treat adults with certain soft-tissue sarcomas, cancers that develop in areas such as the muscles, fat, blood vessels and tendons.

Lartruvo has been sanctioned for use with the chemotherapy drug doxorubicin in cases that cannot be treated with radiation or surgery, the FDA said Wednesday in a news release.

More than 12,000 new cases of soft-tissue sarcoma are projected to be diagnosed this year and nearly 5,000 people are likely to die from the disease, the agency said, citing estimates from the U.S. National Cancer Institute.

Lartruvo is designed to block cell receptors that fuel tumor growth, the FDA said. The drug was evaluated in clinical trials involving 133 people with soft-tissue carcinomas. Average survival among people who took Lartruvo and doxorubicin was 8.2 months, compared with 4.4 months among people who took doxorubicin alone.

Potential side effects identified during the studies included harm to a developing fetus, , fever, chills, nausea, fatigue, low white and musculoskeletal pain.

Lartruvo's maker, Indianapolis-based Eli Lilly and Company, is conducting a larger study to further evaluate the drug's effectiveness among numerous types of soft-tissue sarcoma, the agency said.


Explore further

Combining new and old drugs improves survival for soft-tissue cancer patients

More information: To learn more, visit the Food and Drug Administration.

Copyright © 2016 HealthDay. All rights reserved.

Citation: New treatment approved for soft-tissue cancers (2016, October 19) retrieved 22 October 2019 from https://medicalxpress.com/news/2016-10-treatment-soft-tissue-cancers.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more